$6.85 Billion is the total value of RTW INVESTMENTS, LP's 124 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RCKT | ROCKET PHARMACEUTICALS INC | $344,975,000 | -26.5% | 15,802,802 | 0.0% | 5.04% | -28.9% | |
| PTCT | PTC THERAPEUTICS INC | $210,859,000 | +7.0% | 5,293,966 | 0.0% | 3.08% | +3.6% | |
| VCEL | VERICEL CORP | $177,541,000 | -19.5% | 4,517,570 | 0.0% | 2.59% | -22.0% | |
| TNDM | TANDEM DIABETES CARE INC | $174,714,000 | +26.1% | 1,160,734 | 0.0% | 2.55% | +22.1% | |
| NTRA | NATERA INC | $173,914,000 | -16.2% | 1,862,234 | 0.0% | 2.54% | -18.8% | |
| ESTA | ESTABLISHMENT LABS HLDGS INC | $156,751,000 | -5.6% | 2,319,138 | 0.0% | 2.29% | -8.5% | |
| RXDX | PROMETHEUS BIOSCIENCES INC | $129,060,000 | +66.8% | 3,264,031 | 0.0% | 1.88% | +61.5% | |
| GMED | GLOBUS MED INCcl a | $120,633,000 | -5.8% | 1,670,811 | 0.0% | 1.76% | -8.8% | |
| RNA | AVIDITY BIOSCIENCES INC | $113,977,000 | -3.5% | 4,795,000 | 0.0% | 1.66% | -6.6% | |
| ISEE | IVERIC BIO INC | $112,402,000 | +3.0% | 6,722,624 | 0.0% | 1.64% | -0.3% | |
| ITOS | ITEOS THERAPEUTICS INC | $109,556,000 | +72.4% | 2,353,015 | 0.0% | 1.60% | +67.0% | |
| TXG | 10X GENOMICS INC | $109,408,000 | +2.3% | 734,481 | 0.0% | 1.60% | -0.9% | |
| AXNX | AXONICS INC | $108,856,000 | -14.0% | 1,943,864 | 0.0% | 1.59% | -16.7% | |
| STOK | STOKE THERAPEUTICS INC | $87,426,000 | -5.7% | 3,644,248 | 0.0% | 1.28% | -8.7% | |
| CCCC | C4 THERAPEUTICS INC | $80,338,000 | -27.9% | 2,494,965 | 0.0% | 1.17% | -30.2% | |
| MGNX | MACROGENICS INC | $63,808,000 | -23.4% | 3,975,554 | 0.0% | 0.93% | -25.7% | |
| RGNX | REGENXBIO INC | $60,343,000 | -22.0% | 1,845,366 | 0.0% | 0.88% | -24.5% | |
| GHRS | GH RESEARCH PLCordinary shares | $50,602,000 | +10.7% | 2,168,957 | 0.0% | 0.74% | +7.3% | |
| TENAYA THERAPEUTICS INC | $46,593,000 | -4.1% | 2,458,750 | 0.0% | 0.68% | -7.2% | ||
| AVDL | AVADEL PHARMACEUTICALS PLCsponsored adr | $46,395,000 | -17.6% | 5,741,939 | 0.0% | 0.68% | -20.3% | |
| TARS | TARSUS PHARMACEUTICALS INC | $45,306,000 | +4.4% | 2,013,601 | 0.0% | 0.66% | +1.2% | |
| APYX | APYX MEDICAL CORPORATION | $43,566,000 | -7.4% | 3,398,279 | 0.0% | 0.64% | -10.4% | |
| IMCR | IMMUNOCORE HLDGS PLCads | $42,647,000 | -7.6% | 1,245,532 | 0.0% | 0.62% | -10.5% | |
| OM | OUTSET MED INC | $41,235,000 | -6.8% | 894,652 | 0.0% | 0.60% | -9.7% | |
| EPIX | ESSA PHARMA INC | $37,448,000 | +77.5% | 2,637,192 | 0.0% | 0.55% | +72.0% | |
| LUNG | PULMONX CORP | $37,349,000 | -10.9% | 1,164,600 | 0.0% | 0.54% | -13.8% | |
| MIST | MILESTONE PHARMACEUTICALS IN | $28,264,000 | +14.7% | 4,315,102 | 0.0% | 0.41% | +11.0% | |
| CSTL | CASTLE BIOSCIENCES INC | $25,680,000 | -35.5% | 599,009 | 0.0% | 0.38% | -37.6% | |
| ATHA | ATHIRA PHARMA INC | $24,842,000 | +38.9% | 1,906,557 | 0.0% | 0.36% | +34.4% | |
| GLUE | MONTE ROSA THERAPEUTICS INC | $24,802,000 | -4.6% | 1,214,572 | 0.0% | 0.36% | -7.7% | |
| CERE | CEREVEL THERAPEUTICS HLDNG I | $21,613,000 | +9.9% | 666,666 | 0.0% | 0.32% | +6.4% | |
| LABP | LANDOS BIOPHARMA INC | $20,523,000 | -67.1% | 4,275,722 | 0.0% | 0.30% | -68.1% | |
| AADI BIOSCIENCES INC | $18,468,000 | -13.4% | 764,701 | 0.0% | 0.27% | -16.1% | ||
| BWAY | BRAINSWAY LTDsponsored ads | $12,338,000 | -4.5% | 1,602,381 | 0.0% | 0.18% | -7.7% | |
| LJPC | LA JOLLA PHARMACEUTICAL CO | $10,825,000 | +16.5% | 2,327,903 | 0.0% | 0.16% | +12.9% | |
| NEO | NEOGENOMICS INC | $10,615,000 | -28.6% | 311,111 | 0.0% | 0.16% | -30.8% | |
| XGN | EXAGEN INC | $9,553,000 | -14.5% | 821,414 | 0.0% | 0.14% | -17.3% | |
| URGN | UROGEN PHARMA LTD | $8,154,000 | -43.5% | 857,464 | 0.0% | 0.12% | -45.4% | |
| NYXOAH S A | $7,933,000 | -21.4% | 344,911 | 0.0% | 0.12% | -23.7% | ||
| RACB | RESEARCH ALLIANCE CORP II | $6,192,000 | -1.3% | 637,000 | 0.0% | 0.09% | -5.3% | |
| BLSA | BCLS ACQUISITION CORP | $6,003,000 | -1.6% | 612,500 | 0.0% | 0.09% | -4.3% | |
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $5,698,000 | -13.5% | 1,100,000 | 0.0% | 0.08% | -16.2% | |
| SMIHU | SUMMIT HEALTHCRE ACQUISTN COunit 06/03/2026 | $4,975,000 | -1.0% | 500,000 | 0.0% | 0.07% | -3.9% | |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $4,958,000 | -1.3% | 500,000 | 0.0% | 0.07% | -5.3% | |
| ARYA SCIENCES ACQUISITN CORP | $4,850,000 | -1.8% | 500,000 | 0.0% | 0.07% | -4.1% | ||
| PROCEPT BIOROBOTICS CORP | $4,855,000 | -34.4% | 194,136 | 0.0% | 0.07% | -36.6% | ||
| IMTX | IMMATICS N.V | $4,704,000 | +3.4% | 350,000 | 0.0% | 0.07% | 0.0% | |
| SOPHIA GENETICS SAordinary shares | $4,230,000 | -19.6% | 300,000 | 0.0% | 0.06% | -21.5% | ||
| FVAM | 5 01 ACQUISITION CORP | $3,861,000 | +0.3% | 392,000 | 0.0% | 0.06% | -3.4% | |
| ASLN | ASLAN PHARMACEUTICALS LTDads | $3,640,000 | -37.1% | 3,250,000 | 0.0% | 0.05% | -39.1% | |
| MSAC | MEDICUS SCIENCES ACQUISITION | $2,907,000 | -0.6% | 300,000 | 0.0% | 0.04% | -4.5% | |
| MAXCYTE INC | $2,802,000 | -16.6% | 275,000 | 0.0% | 0.04% | -19.6% | ||
| PNT | POINT BIOPHARMA GLOBAL INC | $2,744,000 | -27.2% | 490,000 | 0.0% | 0.04% | -29.8% | |
| CNTB | CONNECT BIOPHARMA HLDGS LTDads | $2,318,000 | -78.7% | 450,000 | 0.0% | 0.03% | -79.3% | |
| DNAY | CODEX DNA INC | $2,160,000 | -3.0% | 200,000 | 0.0% | 0.03% | -5.9% | |
| MDXG | MIMEDX GROUP INC | $1,786,000 | -0.3% | 295,748 | 0.0% | 0.03% | -3.7% | |
| SEMA4 HOLDINGS CORP | $1,784,000 | -39.2% | 400,000 | 0.0% | 0.03% | -40.9% | ||
| RXSIGHT INC | $1,688,000 | -11.2% | 150,000 | 0.0% | 0.02% | -13.8% | ||
| AKYA | AKOYA BIOSCIENCES INC | $1,531,000 | +9.7% | 100,000 | 0.0% | 0.02% | +4.8% | |
| MIRO | MIROMATRIX MED INC | $1,313,000 | -32.6% | 280,000 | 0.0% | 0.02% | -34.5% | |
| OMIC | SINGULAR GENOMICS SYSTEMS IN | $1,156,000 | +3.3% | 100,000 | 0.0% | 0.02% | 0.0% | |
| MASS | 908 DEVICES INC | $1,035,000 | -20.4% | 40,000 | 0.0% | 0.02% | -25.0% | |
| BOLT | BOLT BIOTHERAPEUTICS INC | $619,000 | -61.3% | 126,365 | 0.0% | 0.01% | -62.5% | |
| ZY | ZYMERGEN INC | $468,000 | -49.2% | 70,000 | 0.0% | 0.01% | -50.0% | |
| RENOVACOR INC*w exp 99/99/999 | $200,000 | -10.7% | 350,000 | 0.0% | 0.00% | 0.0% | ||
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $24,000 | 0.0% | 33,331 | 0.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.